Search

Your search keyword '"Ancell, Kristin K."' showing total 14 results
Start Over Author "Ancell, Kristin K."
14 results on '"Ancell, Kristin K."'

1. Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Author

Tucker, Matthew D., Brown, Landon C., Chen, Yu-Wei, Kao, Chester, Hirshman, Nathan, Kinsey, Emily N., Ancell, Kristin K., Beckermann, Kathryn E., Davis, Nancy B., McAlister, Renee, Schaffer, Kerry, Armstrong, Andrew J., Harrison, Michael R., George, Daniel J., Rathmell, W. Kimryn, Rini, Brian I., and Zhang, Tian

Published
2021
Full Text
View/download PDF

3. The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

Author

Chen, Yu-Wei, primary, Tucker, Matthew D., additional, Brown, Landon C., additional, Yasin, Hesham A., additional, Ancell, Kristin K., additional, Armstrong, Andrew J., additional, Beckermann, Kathryn E., additional, Davis, Nancy B., additional, Harrison, Michael R., additional, Kaiser, Elizabeth G., additional, McAlister, Renee K., additional, Schaffer, Kerry R., additional, Wallace, Deborah E., additional, George, Daniel J., additional, Rathmell, W. Kimryn, additional, Rini, Brian I., additional, and Zhang, Tian, additional

Published
2022
Full Text
View/download PDF

4. Additional file 4 of Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Author

Tucker, Matthew D., Brown, Landon C., Chen, Yu-Wei, Kao, Chester, Hirshman, Nathan, Kinsey, Emily N., Ancell, Kristin K., Beckermann, Kathryn E., Davis, Nancy B., McAlister, Renee, Schaffer, Kerry, Armstrong, Andrew J., Harrison, Michael R., George, Daniel J., Rathmell, W. Kimryn, Rini, Brian I., and Zhang, Tian

Abstract

Additional file 4: Supplemental Figure 3: PFS and OS by median NER and NLR among treatment na��ve patients: A) Median PFS was 14.3 mo in the mNER group (n=41) (HR 0.49, p

Published
2021
Full Text
View/download PDF

5. Additional file 2 of Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Author

Tucker, Matthew D., Brown, Landon C., Chen, Yu-Wei, Kao, Chester, Hirshman, Nathan, Kinsey, Emily N., Ancell, Kristin K., Beckermann, Kathryn E., Davis, Nancy B., McAlister, Renee, Schaffer, Kerry, Armstrong, Andrew J., Harrison, Michael R., George, Daniel J., Rathmell, W. Kimryn, Rini, Brian I., and Zhang, Tian

Abstract

Additional file 2: Supplemental Figure 1: PFS and OS by median NER and NLR among intermediate/poor risk. A) Median PFS was 8.2 mo in the mNER group (n=46) (HR 0.55, p=0.01). B) Median OS was NR in the mNER group (n=46) (HR 0.32, p

Published
2021
Full Text
View/download PDF

6. Additional file 1 of Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Author

Tucker, Matthew D., Brown, Landon C., Chen, Yu-Wei, Kao, Chester, Hirshman, Nathan, Kinsey, Emily N., Ancell, Kristin K., Beckermann, Kathryn E., Davis, Nancy B., McAlister, Renee, Schaffer, Kerry, Armstrong, Andrew J., Harrison, Michael R., George, Daniel J., Rathmell, W. Kimryn, Rini, Brian I., and Zhang, Tian

Subjects
Data_FILES
Abstract

Additional file 1:.

Published
2021
Full Text
View/download PDF

7. Additional file 3 of Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Author

Tucker, Matthew D., Brown, Landon C., Chen, Yu-Wei, Kao, Chester, Hirshman, Nathan, Kinsey, Emily N., Ancell, Kristin K., Beckermann, Kathryn E., Davis, Nancy B., McAlister, Renee, Schaffer, Kerry, Armstrong, Andrew J., Harrison, Michael R., George, Daniel J., Rathmell, W. Kimryn, Rini, Brian I., and Zhang, Tian

Abstract

Additional file 3: Supplemental Figure 2: PFS and OS by median NER and NLR among favorable risk. A) Median PFS was 34.0 mo in the mNER group (n=9) (HR 0.33, p=0.07). B) Median OS was NR in the mNER group (n=9) (HR 0.56, p=0.64). C) Median PFS was 5.9 mo in the mNLR group (n=9) (HR 0.89, p=0.84). D) Median OS was NR in the mNLR group (n=9) (HR 1.64, p=0.69).

Published
2021
Full Text
View/download PDF

10. Hematologic Complications of Immune Checkpoint Inhibitors

Author

Davis, Elizabeth J., primary, Salem, Joe-Elie, additional, Young, Arissa, additional, Green, Jennifer R., additional, Ferrell, P. Brent, additional, Ancell, Kristin K., additional, Lebrun-Vignes, Benedicte, additional, Moslehi, Javid J., additional, and Johnson, Douglas B., additional

Published
2019
Full Text
View/download PDF

12. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

Author

Wang, Daniel Y., primary, Salem, Joe-Elie, additional, Cohen, Justine V., additional, Chandra, Sunandana, additional, Menzer, Christian, additional, Ye, Fei, additional, Zhao, Shilin, additional, Das, Satya, additional, Beckermann, Kathryn E., additional, Ha, Lisa, additional, Rathmell, W. Kimryn, additional, Ancell, Kristin K., additional, Balko, Justin M., additional, Bowman, Caitlin, additional, Davis, Elizabeth J., additional, Chism, David D., additional, Horn, Leora, additional, Long, Georgina V., additional, Carlino, Matteo S., additional, Lebrun-Vignes, Benedicte, additional, Eroglu, Zeynep, additional, Hassel, Jessica C., additional, Menzies, Alexander M., additional, Sosman, Jeffrey A., additional, Sullivan, Ryan J., additional, Moslehi, Javid J., additional, and Johnson, Douglas B., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results